Razaro-LS Capsule SR
Manufacturer
Lexaro Healthcare
Salt Composition
Levosulpiride (75mg) + Rabeprazole (20mg)
Key Information
Short Description
Razaro-LS Capsule SR is a prescription medicine used to treat gastroesophageal reflux disease (acid reflux), intestinal ulcers, and irritable bowel syndrome.
Dosage Form
Capsule SR
Introduction
Razaro-LS Capsule SR is taken with or without food in a dose and duration as advised by the doctor. The dose you are given will depend on your condition and how you respond to the medicine. You should keep taking this medicine for as long as your doctor recommends. If you stop treatment too early your symptoms may come back and your condition may worsen. Let your healthcare team know about all other medications you are taking as some may affect or be affected by this medicine.
Directions for Use
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Razaro-LS Capsule SR is to be taken empty stomach.
Safety Information
Side Effects
The most common side effects are nausea, stomach pain, diarrhea, flatulence, constipation, headache, weakness, and flu-like symptoms.
Alcohol Warning
It is unsafe to consume alcohol with Razaro-LS Capsule SR.
Breastfeeding Warning
Information regarding the use of Razaro-LS Capsule SR during breastfeeding is not available. Please consult your doctor.
Pregnancy Warning
Razaro-LS Capsule SR may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
How it works
Razaro-LS Capsule SR is a combination of two medicines: Levosulpiride and Rabeprazole.
Quick Tips
Do not consume alcohol while taking Razaro-LS Capsule SR as it can increase the risk of stomach damage. Long-term use may cause weak or broken bones. Take adequate intake of dietary calcium and vitamin D or their supplements. Do not take Razaro-LS Capsule SR for longer than prescribed.
Related Medicines
Colosafe-L Capsule SR
Rablet L Capsules
Ansuper-Plus Capsule SR
Acera-L Capsule SR
Rabemac LS Capsule
Veloz L Capsule
Rabonik Plus Capsule SR
Razo-L Capsule
Ripra-LSR 75mg/20mg Capsule
Rabvive-L Capsule SR
Frequently asked questions
What are the recommended timings for taking Razaro-LS Capsule SR?
Take one Razaro-LS Capsule SR exactly as prescribed by your doctor. It is best to take the capsule on an empty stomach.
Are there any contraindications or precautions associated with using Razaro-LS Capsule SR?
Do not use Razaro-LS Capsule SR if you have a known allergy to any component of this medicine or excipients. Additionally, it is important to inform your doctor about any other medications you are taking before starting this treatment.
Can Razaro-LS Capsule SR cause dizziness?
Yes, some individuals may experience dizziness (feeling faint, weak, unsteady, or lightheaded) while using Razaro-LS Capsule SR. If you experience dizziness or any other side effects, please rest and resume activities once you feel better.
Does the use of Razaro-LS Capsule SR increase the risk of fractures?
Research suggests that treatment with Razaro-LS Capsule SR might be associated with an increased risk of osteoporosis-related fractures (hip, wrist, or spine). This risk is more significant in individuals receiving higher doses (multiple daily doses and long-term therapy for a year or longer).
Can I drive safely while taking Razaro-LS Capsule SR?
Taking Razaro-LS Capsule SR may cause drowsiness, dizziness, or blurred vision. It is essential to avoid driving or operating machinery until you understand the effects of this medication on your body.
What are the instructions for storage and disposal of Razaro-LS Capsule SR?
Store Razaro-LS Capsule SR in its original packaging, tightly sealed. Follow the storage directions on the label provided with the medicine. Dispose of unused medication according to local regulations and do not allow children or pets to access it.
